Correlation Engine 2.0
Clear Search sequence regions
Bookmark Forward

QuickView for Thiabendazole (compound)


PubChem
Name: Thiabendazole
PubChem Compound ID: 5430
Description: 2-Substituted benzimidazole first introduced in 1962. It is active against a variety of nematodes and is the drug of choice for STRONGYLOIDIASIS. It has CENTRAL NERVOUS SYSTEM side effects and hepatototoxic potential. (From Smith and Reynard, Textbook of Pharmacology, 1992, p919)
Molecular formula: C10H7N3S
Molecular weight: 201.249 g/mol
Synonyms:
SMR000058170; CCRIS 4510; NINDS_000072; G 491; Ormogal; 8027-10-9; Sistesan; 4-(2-benzimidazolyl)thiazole; Tiabendazol [INN-Spanish, French]; Spectrum2_001331.
show more »
DrugBank
Identification
Name: Thiabendazole
Name (isomeric): DB00730
Drug Type: small molecule
Description: 2-Substituted benzimidazole first introduced in 1962. It is active against a variety of nematodes and is the drug of choice for STRONGYLOIDIASIS. It has CENTRAL NERVOUS SYSTEM side effects and hepatototoxic potential. (From Smith and Reynard, Textbook of Pharmacology, 1992, p919)
Synonyms:
TBDZ; Thiabenzazole; Thiabendazol; Thiabenzole; Tiabendazole; TBZ; 2-(1,3-Thiazol-4-yl)-1H-benzimidazole; Thiabendole; Tiabendazol
Brand: TBZ 6, Triasox, Thibenzole att, Ormogal, Thibenzole 200, Hokustar hp, Minzolum, Apl-Luster, Tecto rph, Tecto B, Tubazole, Mertect 160, Tecto 10P, Mycozol, Eprofil, Hymush, Sanaizol 100, Mertect 340f, Tecto 40F, Tiabenda, Bioguard, Drawipas, TBZ 60W, Top form wormer, Lombristop, Thiprazole, Tobaz, Metasol TK 100, Mintesol, Sistesan, Polival, Mertec, Tecto 60, Thiaben, Mintezol, Equivet TZ, Cropasal, Equizole, Tebuzate, Arbotect, Nemapan, Omnizole, Thibenzole, Mertect, Nemacin, Thibendole, Tibimix 20, Bovizole, Tecto, Metasol TK 10, Storite, Thibenzol, Chemviron TK 100, Mertect lsp, Testo, RPH
Brand name mixture: Tresaderm Dermatologic Solution(Dexamethasone + Neomycin sulfate + Thiabendazole)
Category: Anthelmintics, Antinematodal Agents
CAS number: 148-79-8
Pharmacology
Indication: For the treatment of strongyloidiasis (threadworm), cutaneous larva migrans (creeping eruption), visceral larva migrans, and trichinosis.
Pharmacology:
Thiabendazole is a fungicide and parasiticide. Thiabendazole is also a chelating agent, which means that it is used medicinally to bind metals in cases of metal poisoning, such as lead poisoning, mercury poisoning or antimony poisoning. Thiabendazole is vermicidal and/or vermifugal against Ascaris lumbricoides ("common roundworm"), Strong...
show more »
Mechanism of Action: The precise mode of action of thiabendazole on the parasite is unknown, but it most likely inhibits the helminth-specific enzyme fumarate reductase.
Absorption: Rapidly absorbed and peak plasma concentration is reached within 1 to 2 hours after the oral administration of a suspension. Some systemic absorption may occur from topical preparations applied to the skin.
Biotransformation: Hepatic. Metabolized almost completely to the 5-hydroxy form which appears in the urine as glucuronide or sulfate conjugates.
Route of elimination: It is metabolized almost completely to the 5-hydroxy form which appears in the urine as glucuronide or sulfate conjugates.
Half Life: The half-life for thiabendazole in both normal and anephric patients is 1.2 hours (range 0.9 to 2 hours). The half-life for the 5-hydroxythiabendazole metabolite in both normal and anephric patients is 1.7 hours (range 1.4 to 2 hours).
Toxicity: Overdosage may be associated with transient disturbances of vision and psychic alterations. The oral LD 50 is 3.6 g/kg, 3.1 g/kg and 3.8 g/kg in the mouse, rat, and rabbit respectively.
Affected organisms: Roundworms, hookworms, and other helminth species
Interactions
Drug interaction:
AcenocoumarolThe strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Acenocoumarol by decreasing Acenocoumarol metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Acenocoumarol if Thiabendazole is initiated, discontinued or dose changed.
DuloxetineThe strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Duloxetine by decreasing Duloxetine metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Duloxetine if Thiabendazole is initiated, discontinued or dose changed.
ThiothixeneThe strong CYP1A2 inhibitor, Thiobendazole, may decrease the metabolism and clearance of Thiothixene, a CYP1A2 substrate. Consider alternate therapy or monitor for changes in Thiothixene therapeutic and adverse effects if Thiobendazole is initiated, discontinued or dose changed.
RamelteonThiabendazole increases levels/toxicity of ramelteon
AlosetronThe strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Alosetron by decreasing Alosetron metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Alosetron if Thiabendazole is initiated, discontinued or dose changed.
show more »

Targets


Enzymes